3 Stocks We Love in 2026 - motley-fool-money Recap

Podcast: motley-fool-money

Published: 2025-12-31

Duration: 24 minutes

Guests: Lou Whiteman, Rachel Warren

Summary

This episode highlights investment opportunities in 2026, focusing on the space and healthcare sectors. Experts discuss Rocket Lab, TransMedics, and Hims & Hers, providing insights into their potential growth and associated risks.

What Happened

Lou Whiteman kicks off the episode with a discussion on the potential of the space sector in 2026, highlighting Rocket Lab as a leader with promising prospects. He also mentions the speculative nature of the industry, citing companies like Redwire as high-risk investments with potential high rewards, especially if SpaceX goes public with a rumored $1.5 trillion valuation.

The conversation shifts to the challenges and opportunities within the space industry, addressing the profitability of companies like Rocket Lab and Redwire. Lou notes that while many space startups are currently unprofitable, strategic partnerships and technological advancements could offer significant returns.

Rachel Warren turns to the healthcare sector, introducing TransMedics, a company revolutionizing organ transplantation with its FDA-approved Organ Care System. She highlights the company's innovative approach to organ transportation and its expansion into international markets like Italy, emphasizing its market leadership and potential for growth.

Rachel further explores the financial stability of TransMedics, noting its profitability and high-margin recurring revenue streams. She mentions the company's ongoing clinical trials, which could significantly expand its market share and drive future growth if successful.

Travis Hoium discusses Hims & Hers, a healthcare company disrupting traditional models by offering telehealth services and compounding facilities. He highlights the company's innovative approach to healthcare, likening it to Netflix's demand aggregation model, and notes its ventures into various medical fields beyond its weight loss offerings.

The episode also covers the risks and controversies surrounding Hims & Hers, particularly its involvement with GLP-1 weight loss medications and the legal complexities of compounding. Despite these challenges, the company is positioned to capitalize on the growing demand for telehealth services.

Lou expresses cautious optimism about Hims & Hers, acknowledging the need for disruption in the healthcare sector. He advises careful consideration of the company's management strategy, given the potential legal and ethical challenges involved in its business model.

Key Insights

• Rocket Lab is positioned as a leader in the space sector for 2026, with potential high returns despite the speculative nature of the industry. The company's future prospects may be influenced by SpaceX's potential public offering, rumored to be valued at $1.5 trillion.
• TransMedics is transforming organ transplantation with its FDA-approved Organ Care System, which is expanding into international markets like Italy. The company's profitability and high-margin recurring revenue streams are bolstered by ongoing clinical trials that could expand its market share.
• Hims & Hers is disrupting traditional healthcare models by offering telehealth services and compounding facilities, drawing parallels to Netflix's demand aggregation model. The company faces legal complexities with GLP-1 weight loss medications but is well-positioned to meet the growing demand for telehealth.
• The space industry faces challenges in profitability, but strategic partnerships and technological advancements could yield significant returns. Companies like Rocket Lab and Redwire are currently unprofitable, highlighting the high-risk, high-reward nature of investing in space startups.